Can an RNAi drug shrink Hard-to-Treat tumors?

NCT ID NCT05037149

Completed Disease control Sponsor: Sirnaomics Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase 1 trial is testing an experimental drug called STP707 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see whether the drug can slow or shrink tumors. Participants receive STP707 by intravenous infusion, and researchers monitor for side effects and anti-tumor activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental RNAi drug called STP707
What this could lead to: If safe and effective, STP707 could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early phase 1 trial with only 50 participants, so the drug may not prove effective or may cause unexpected side effects. It is too early to know if it will work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Atlantic Health System

Morristown, New Jersey, 07960, United States
Emory University

Atlanta, Georgia, 30322, United States
Mayo Clinic

Phoenix, Arizona, 85054, United States
Mayo Clinic

Jacksonville, Florida, 32224, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
NEXT Oncology

Austin, Texas, 78758, United States
Sarah Cannon Research Institute at HealthONE

Denver, Colorado, 80218, United States
USC Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
Yale University

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.